Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Idarubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.98 |
| ▸ | ECE1 | P42892 | 1/20 | 1.00 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 0.98 |
| ▸ | THRB | P10828 | 10/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.98 |
| ▸ | BLM | P54132 | 9/20 | 0.98 |
| ▸ | RECQL | P46063 | 8/20 | 0.98 |
| ▸ | MAPT | P10636 | 7/20 | 0.98 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.98 |
| ▸ | HTT | P42858 | 5/20 | 0.98 |
| ▸ | USP2 | O75604 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.98 |
| ▸ | S100A4 | P26447 | 5/20 | 0.98 |
| ▸ | STAT6 | P42226 | 5/20 | 0.98 |
| ▸ | NPC1 | O15118 | 4/20 | 0.98 |
| ▸ | RAB9A | P51151 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Idarubicin SCHEMBL454665 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL29367370 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL4838 | 1.00 | ECE1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL20838939 | 0.99 | ECE1 (0.98) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL16606206 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL7029978 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL16609956 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL20541733 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL15159345 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A | |
| Idarubicin SCHEMBL12257447 | 0.99 | MEN1 (1.00) | ECE1MUS81MEN1THRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007149103-A2 | VASCULAR TISSUE ENHANCEMENT AND SELECTIVE DESTRUCTION OF CANCEROUS CELLULAR TISSUE | KAISER DANIEL E (US) | 2007-12-27 | — | — | WO | claimed |
| US-20220008451-A1 | FLAVIN ADENINE DINUCLEOTIDE (FAD) FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | BIO EVEN (FR) | 2022-01-13 | — | — | US | disclosed |
| EP-3873485-A1 | FLAVIN ADENINE DINUCLEOTIDE (FAD) FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | Bio Even (FR) | 2021-09-08 | — | — | EP | disclosed |
| EP-3426249-A1 | SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY | The Regents of The University of Michigan (US) | 2019-01-16 | — | — | EP | disclosed |
| US-20180360784-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF MIGRAINE | 3E THERAPEUTICS CORPORATION | 2018-12-20 | — | — | US | disclosed |
| WO-2018081719-A1 | SMALL MOLECULE INHIBITORS OF NEK2 AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2018-05-03 | — | — | WO | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017184751-A1 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING HYPERTENSION | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017165663-A1 | BIOMARKERS FOR CANCER ASSOCIATED WITH HEDGEHOG PATHWAY ACTIVITY AND RELATED USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017155991-A1 | SMALL MOLECULE INDUCERS OF REACTIVE OXYGEN SPECIES AND INHIBITORS OF MITOCHONDRIAL ACTIVITY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-09-14 | — | — | WO | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| EP-2970965-A2 | DNAI FOR THE MODULATION OF GENES | Pronai Therapeutics, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150290158-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS | LASSER ELLIOTT C (US) | 2015-10-15 | — | — | US | disclosed |
| EP-2916831-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT INFLAMMATION ASSOCIATED CONDITIONS | 3E Therapeutics Corporation (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014144942-A2 | DNAI FOR THE MODULATION OF GENES | PRONAI THERAPEUTICS, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014134038-A1 | COMPOSITIONS AND METHODS RELATING TO INDUCTION OF INTESTINAL STEM CELL HOMEOGENESIS AND/OR REGENERATION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014085485-A1 | METHODS AND COMPOSITIONS FOR TARGETING CANCER STEM CELLS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014074744-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT INFLAMMATION ASSOCIATED CONDITIONS | LASSER ELLIOTT C (US) | 2014-05-15 | — | — | WO | disclosed |
| CN-102439454-A | Molecular profiling of tumors | CARIS MPI INC | 2012-05-02 | — | — | CN | disclosed |
| US-20050244857-A1 | Death domain containing receptor 4 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008451-A1 | FLAVIN ADENINE DINUCLEOTIDE (FAD) FOR USE IN THE PREVENTION AND/OR TREATMENT OF CANCER | NQO1, FLAD1, DPYD | TOP2A 1671/4885ECE1 1417/4885MUS81 2128/4885 |
| US-20150290158-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF CNS INFLAMMATION AND INFLAMMATION ASSOCIATED CONDITIONS | CHI3L2, CHI3L1, CCR1 | TOP2A 1271/4885ECE1 1601/4885MUS81 3956/4885 |
| US-20180360784-A1 | X-RAY CONTRAST MEDIA COMPOSITIONS AND METHODS OF USING THE SAME TO TREAT, REDUCE OR DELAY THE ONSET OF MIGRAINE | CALCA, CALCB, CALCR | TOP2A 926/4885ECE1 819/4885MUS81 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.